Loading
New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma.
John Leonard is a lymphoma specialist and senior leader at Weill Cornell Medicine in New York. He was first author of the 2019 Journal of Clinical Oncology report of AUGMENT, which showed that lenalidomide plus rituximab improved progression-free survival compared with rituximab alone in relapsed or refractory indolent lymphoma, leading to the combination's approval. He has led many cooperative-group trials in indolent and aggressive B-cell lymphoma.
| Title | Journal | Year |
|---|---|---|
| AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma | Journal of Clinical Oncology | 2019 |
Shares Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Follicular lymphoma and the tags lymphoma, trialist.
Shares Non-Hodgkin lymphoma (all types) and the tags lymphoma, trialist.
Shares the tags lymphoma, trialist.
Shares Marginal zone lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag lymphoma.
Shares Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine and the tag trialist.
Shares Marginal zone lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag lymphoma.